OneSource Specialty Pharma announced that its partner, Orbicular, has received approval from Health Canada for a generic version of Ozempic (semaglutide injection). This marks the second approval for generic semaglutide in Canada, establishing OneSource and Orbicular as the first generic entrants in a significant market. The product development was led by Orbicular, while OneSource provided comprehensive manufacturing support, utilizing its US FDA-approved facility in Bengaluru for commercial supply. This approval follows a recent tentative approval in the United States, further solidifying OneSource's position in complex peptide-based injectable programs. Neeraj Sharma, CEO & MD of OneSource, expressed satisfaction with the back-to-back approvals, emphasizing the strength of their contract development and manufacturing organization (CDMO) platform and collaborative partnerships for global commercialization.